Fig. 4: Trajectory of baseline and cycle 3 ctDNA scores by response status. | npj Precision Oncology

Fig. 4: Trajectory of baseline and cycle 3 ctDNA scores by response status.

From: Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

Fig. 4: Trajectory of baseline and cycle 3 ctDNA scores by response status.The alternative text for this image may have been generated using AI.

ctDNA dynamics between baseline and C3 timepoints in patients with available results (n = 58). ctDNA scores are represented in log10 scale (y-axis) between timepoints (x-axis) and stratified according to treatment response groups. Left panel: Complete Response/Partial Response; Middle panel: Stable Disease ≥6 cycles; Right panel: Stable Disease <6 cycles/Progressive Disease. ctDNA scores decreased from baseline to C3 are presented in green lines, whereas those that increased are in red. Hollow dots represent ctDNA scores below the reportable threshold, while solid dots are ctDNA scores above. C3 cycle 3, CR complete response, PD progressive disease, PR partial response, SD stable disease.

Back to article page